Respiratory Syncytial Virus (RSV) symptoms are similar to the flu. Older adults are more at risk of developing severe illnesses such as pneumonia that in some cases may lead to respiratory failure. So far, there is no specific vaccine available against RSV. This research study is evaluating an investigational RSV vaccine for adults 60 years of age or older. Other criteria apply.
Qualified participants will receive the vaccine (or placebo) and study-related care at no cost. Financial compensation will also be provided for time and travel expenses.
Interested? Start a conversation: 314-514-8509 / www.clinicalresearchcenter.com